Feb 22, 2022
Code Biotherapeutics, Inc. (Code Bio), a biotechnology company pioneering targeted non-viral delivery of genetic medicines, today announced a collaboration and option agreement with Takeda to leverage Code Bio’s proprietary targeted 3DNA® non-viral genetic medicine delivery platform to design and develop gene therapies for rare disease indications.
Read more at https://www.codebiotx.com/news-february-22-2022